Generali Asset Management’s Royalty Pharma RPRX Stock Holding History

Generali Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.6K	Sell	429 -5	-1%	-$219	﹤0.01%	466
2025 Q4	$16.8K	Sell	434 -33,647	-99%	-$1.28M	﹤0.01%	468
2025 Q3	$1.2M	Buy	34,081 +33,647	+7,753%	+$1.22M	0.03%	388
2025 Q2	$15.6K	Sell	434 -94,251	-100%	-$3.12M	﹤0.01%	488
2025 Q1	$2.95M	Buy	94,685 +94,232	+20,802%	+$2.99M	0.07%	239
2024 Q4	$11.6K	Buy	+453	New	+$12K	﹤0.01%	470

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Generali Asset Management's RPRX Position: Q1 2026 in Review

Generali Asset Management reduced its Royalty Pharma (RPRX) stake by 1.2% in Q1 2026, selling an estimated $219 and leaving 429 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #466.

Generali Asset Management first reported a position in RPRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.95M in Q1 2025. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Generali Asset Management held 429 shares of Royalty Pharma worth $20.6K as of Q1 2026.
Generali Asset Management sold 5 Royalty Pharma shares in Q1 2026, an estimated $219.
Royalty Pharma made up ﹤0.01% of Generali Asset Management's portfolio in Q1 2026, its #466 holding.
Generali Asset Management first reported a position in Royalty Pharma in Q4 2024 and has held it in 6 quarters since.
Generali Asset Management's Royalty Pharma position peaked at $2.95M in Q1 2025.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Generali Asset Management's 13F filing for Q1 2026, filed 5 May 2026.